Lupin launches authorized generic of Femcon
Srujani Panda / 11 Oct 2011
Lupin Pharmaceuticals Inc. (LPI), a subsidiary of Lupin Ltd has launched the Authorized Generic of ‘Femcon Fe’ Chewable tablets in the USA. The authorized generic product will be manufactured by a pharma company, Warner Chilcott. Femcon Fe is a 0.4 mg / 35 mcg low-dose chewable birth control tablet that can also be swallowed immediately followed by a full glass (8 oz) of liquid. It contains Norethindrone and Ethinyl Estradiol in its formulations.
Size of US oral contraceptive (OC) market is approximately $5 billion. The market size of Femcon Fe is about $50 million. Lupin is targeting about $100m revenues from the sale of OC products in next three years.
Company is also filing OC products in regions like Europe. Other companies in OC segment include Watson and Teva pharmaceuticals. However according company spokesperson, Lupin is the only company which is vertically integrated in OC segment.
Lupin is the fifth largest generic player in terms of prescriptions according to IMS health. Currently Lupin has a robust pipeline of 26 products in OC with full access to value chain including manufacturing facilities.
We at DSIJ believe that entering in oral contraceptive market will largely benefit the company given the size of the market and robust pipeline in this segment. Company also has presence in emerging markets. With the entry in this therapeutic segment one can see good growth prospects for the company.
Size of US oral contraceptive (OC) market is approximately $5 billion. The market size of Femcon Fe is about $50 million. Lupin is targeting about $100m revenues from the sale of OC products in next three years.
Company is also filing OC products in regions like Europe. Other companies in OC segment include Watson and Teva pharmaceuticals. However according company spokesperson, Lupin is the only company which is vertically integrated in OC segment.
Lupin is the fifth largest generic player in terms of prescriptions according to IMS health. Currently Lupin has a robust pipeline of 26 products in OC with full access to value chain including manufacturing facilities.
We at DSIJ believe that entering in oral contraceptive market will largely benefit the company given the size of the market and robust pipeline in this segment. Company also has presence in emerging markets. With the entry in this therapeutic segment one can see good growth prospects for the company.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.